Loading
A phase 1 trial of ORM-6151 (BMS-986497) run by Bristol-Myers Squibb, terminated.
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome is a phase 1 interventional study registered as NCT06419634 by Bristol-Myers Squibb, with 34 participants enrolled, started 2024-05-29. Conditions recorded: Acute Myeloid Leukemia and Myelodysplastic Syndrome. Interventions recorded: BMS-986497, Azacitidine and Venetoclax.
Shares Orum Therapeutics, Acute myeloid leukaemia and the tag pipeline.
Shares Bristol Myers Squibb, Acute myeloid leukaemia and the tag pipeline.
Shares Orum Therapeutics, Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Orum Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/